{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:12:40Z","timestamp":1788581560662,"version":"build-2803163510"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.vph.2026.107671","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T17:40:09Z","timestamp":1781458809000},"page":"107671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Reassessing the role of PPARgamma in vascular effects of cannabinoids: A critical appraisal"],"prefix":"10.1016","volume":"164","author":[{"given":"Olga","family":"Panasiuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kavertseva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandu","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander I.","family":"Bondarenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2026.107671_bb0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrcardio.2017.130","article-title":"Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly","volume":"15","author":"Pacher","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.vph.2026.107671_bb0010","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/HJH.0000000000002333","article-title":"Vasodilatory effects of cannabidiol in human pulmonary and rat small mesenteric arteries: modification by hypertension and the potential pharmacological opportunities","volume":"38","author":"Baranowska-Kuczko","year":"2020","journal-title":"J. Hypertens."},{"key":"10.1016\/j.vph.2026.107671_bb0015","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1111\/j.1476-5381.2011.01747.x","article-title":"Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?","volume":"165","author":"Malinowska","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0090-6980(00)00056-3","article-title":"Cardiovascular effects of endocannabinoids--the plot thickens","volume":"61","author":"Kunos","year":"2000","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.vph.2026.107671_bb0025","doi-asserted-by":"crossref","first-page":"14136","DOI":"10.1073\/pnas.96.24.14136","article-title":"Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors","volume":"96","author":"Jarai","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.vph.2026.107671_bb0030","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1124\/mol.63.3.699","article-title":"Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor","volume":"63","author":"Offertaler","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0035","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1111\/bph.13107","article-title":"The GPR55 agonist lysophosphatidylinositol relaxes rat mesenteric resistance artery and induces Ca(2+) release in rat mesenteric artery endothelial cells","volume":"172","author":"AlSuleimani","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0040","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.phrs.2012.05.004","article-title":"Endothelium-dependent mechanisms of the vasodilatory effect of the endocannabinoid, anandamide, in the rat pulmonary artery","volume":"66","author":"Baranowska-Kuczko","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.vph.2026.107671_bb0045","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/sj.bjp.0707470","article-title":"Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16) in the rat","volume":"152","author":"Hoi","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lfs.2017.11.020","article-title":"Mechanisms of l-alpha-lysophosphatidylinositol-induced relaxation in human pulmonary arteries","volume":"192","author":"Karpinska","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.vph.2026.107671_bb0055","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1476-5381.2009.00622.x","article-title":"N-arachidonoyl glycine, an endogenous lipid that acts as a vasorelaxant via nitric oxide and large conductance calcium-activated potassium channels","volume":"160","author":"Parmar","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0060","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/sj.bjp.0701361","article-title":"Evidence that anandamide and EDHF act via different mechanisms in rat isolated mesenteric arteries","volume":"121","author":"Plane","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0065","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/sj.bjp.0707423","article-title":"Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors","volume":"152","author":"O\u2019Sullivan","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0070","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/bph.13497","article-title":"An update on PPAR activation by cannabinoids","volume":"173","author":"O\u2019Sullivan","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154771","article-title":"Cannabidiol goes nuclear: the role of PPARgamma","volume":"114","author":"Khosropoor","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.vph.2026.107671_bb0080","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1124\/jpet.108.144717","article-title":"The endogenous brain constituent N-arachidonoyl L-serine is an activator of large conductance Ca2+-activated K+ channels","volume":"328","author":"Godlewski","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.vph.2026.107671_bb0085","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.vph.2018.01.004","article-title":"The quest for endothelial atypical cannabinoid receptor: BKCa channels act as cellular sensors for cannabinoids in in vitro and in situ endothelial cells","volume":"102","author":"Bondarenko","year":"2018","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0090","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00424-011-0977-7","article-title":"The GPR55 agonist lysophosphatidylinositol directly activates intermediate-conductance Ca2+-activated K+ channels","volume":"462","author":"Bondarenko","year":"2011","journal-title":"Pflugers Arch. - Eur. J. Physiol."},{"key":"10.1016\/j.vph.2026.107671_bb0095","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1476-5381.2010.00744.x","article-title":"GPR55-dependent and -independent ion signalling in response to lysophosphatidylinositol in endothelial cells","volume":"161","author":"Bondarenko","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0100","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1111\/bph.13312","article-title":"Role of endothelial TRPV4 channels in vascular actions of the endocannabinoid, 2-arachidonoylglycerol","volume":"172","author":"Ho","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0105","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1748-1716.2011.02338.x","article-title":"Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation","volume":"204","author":"De Petrocellis","year":"2012","journal-title":"Acta Physiol."},{"key":"10.1016\/j.vph.2026.107671_bb0110","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fnmol.2018.00487","article-title":"Cannabinoid ligands targeting TRP channels","volume":"11","author":"Muller","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.vph.2026.107671_bb0115","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1111\/bph.12866","article-title":"Endothelial atypical cannabinoid receptor: do we have enough evidence?","volume":"171","author":"Bondarenko","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0120","series-title":"Recent Advances in Cannabinoid Physiology and Pathology","first-page":"63","article-title":"Cannabinoids and Cardiovascular System","author":"Bondarenko","year":"2019"},{"key":"10.1016\/j.vph.2026.107671_bb0125","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","article-title":"PPAR control of metabolism and cardiovascular functions","volume":"18","author":"Montaigne","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.vph.2026.107671_bb0130","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/47254","article-title":"Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension","volume":"402","author":"Barroso","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.vph.2026.107671_bb0135","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/HYPERTENSIONAHA.109.144170","article-title":"Endothelial and vascular muscle PPAR\u03b3 in arterial pressure regulation: lessons from genetic interference and deficiency","volume":"55","author":"Sigmund","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2026.107671_bb0140","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/HYPERTENSIONAHA.117.10799","article-title":"Endothelial PPAR\u03b3 (peroxisome proliferator\u2013activated receptor-\u03b3) is essential for preventing endothelial dysfunction with aging","volume":"72","author":"De Silva","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2026.107671_bb0145","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1161\/HYPERTENSIONAHA.117.09358","article-title":"Genetic interference with endothelial PPAR-\u03b3 (peroxisome proliferator\u2013activated receptor-\u03b3) augments effects of angiotensin II while impairing responses to angiotensin 1\u20137","volume":"70","author":"De Silva","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2026.107671_bb0150","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1152\/physiolgenomics.00087.2015","article-title":"Interference with PPAR\u03b3 in endothelium accelerates angiotensin II-induced endothelial dysfunction","volume":"48","author":"Hu","year":"2016","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.vph.2026.107671_bb0155","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/HYPERTENSIONAHA.118.11857","article-title":"Interference with endothelial PPAR (peroxisome proliferator-activated receptor)-gamma causes accelerated cerebral vascular dysfunction in response to endogenous renin-angiotensin system activation","volume":"72","author":"Nair","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2026.107671_bb0160","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.amjhyper.2004.10.032","article-title":"PPARgamma in endothelial cells influences high fat diet-induced hypertension","volume":"18","author":"Nicol","year":"2005","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.vph.2026.107671_bb0165","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1161\/CIRCRESAHA.108.176339","article-title":"Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet","volume":"103","author":"Beyer","year":"2008","journal-title":"Circ. Res."},{"key":"10.1016\/j.vph.2026.107671_bb0170","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bcp.2014.07.018","article-title":"Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARgamma): a review","volume":"92","author":"Wang","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0175","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1074\/jbc.272.6.3406","article-title":"Peroxisome proliferator-activated receptors \u03b1 and \u03b3 are activated by indomethacin and other non-steroidal anti-inflammatory drugs","volume":"272","author":"Lehmann","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2026.107671_bb0180","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00210-013-0846-3","article-title":"Relaxation of human pulmonary arteries by PPARgamma agonists","volume":"386","author":"Kozlowska","year":"2013","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0185","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1254\/jphs.08117FP","article-title":"Mechanisms underlying pioglitazone-mediated relaxation in isolated blood vessel","volume":"108","author":"Nomura","year":"2008","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.vph.2026.107671_bb0190","article-title":"Anandamide and delta 9-THC dilation of cerebral arterioles is blocked by indomethacin","volume":"269","author":"Ellis","year":"1995","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.vph.2026.107671_bb0195","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/bph.12560","article-title":"Vascular targets for cannabinoids: animal and human studies","volume":"171","author":"Stanley","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0200","series-title":"16th Annual Symposium on the Cannabinoids","article-title":"Cannabinoid ligands as activators of peroxisome proliferator-activated receptor gamma (PPARg)","author":"O\u2019Sullivan","year":"2006"},{"key":"10.1016\/j.vph.2026.107671_bb0205","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.bbrc.2005.09.121","article-title":"Novel time-dependent vascular actions of \u03949-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma","volume":"337","author":"O\u2019Sullivan","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.vph.2026.107671_bb0210","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejphar.2009.03.010","article-title":"Time-dependent vascular actions of cannabidiol in the rat aorta","volume":"612","author":"O\u2019Sullivan","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0215","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/sj.bjp.0705643","article-title":"Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA)","volume":"141","author":"O\u2019Sullivan","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0220","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejphar.2005.05.032","article-title":"Anandamide induced PPAR\u03b3 transcriptional activation and 3T3-L1 preadipocyte differentiation","volume":"517","author":"Bouaboula","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0225","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/sj.bjp.0707404","article-title":"Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta","volume":"152","author":"Herradon","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0230","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/sj.bjp.0705810","article-title":"Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries","volume":"142","author":"O\u2019Sullivan","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0235","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejphar.2017.03.038","article-title":"Direct activation of Ca2+ and voltage-gated potassium channels of large conductance by anandamide in endothelial cells does not support the presence of endothelial atypical cannabinoid receptor","volume":"805","author":"Bondarenko","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.821758","article-title":"Cannabidiol inhibits multiple ion channels in rabbit ventricular cardiomyocytes","volume":"13","author":"Isaev","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0245","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s42238-026-00436-6","article-title":"Electrophysiological modulation of pain-related sodium channels by cannabinoids: a systematic review","volume":"8","author":"Castro","year":"2026","journal-title":"J. Cannabis Res."},{"key":"10.1016\/j.vph.2026.107671_bb0250","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature02282","article-title":"Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1","volume":"427","author":"Jordt","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.vph.2026.107671_bb0255","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1124\/jpet.107.134809","article-title":"Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8","volume":"325","author":"De Petrocellis","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.vph.2026.107671_bb0260","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1097\/HJH.0b013e3282ef7a0a","article-title":"Identification of the vasodilatory endothelial cannabinoid receptor in the human pulmonary artery","volume":"25","author":"Kozlowska","year":"2007","journal-title":"J. Hypertens."},{"key":"10.1016\/j.vph.2026.107671_bb0265","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/bph.12180","article-title":"N-arachidonoyl glycine suppresses Na+\/Ca2+ exchanger-mediated Ca2+ entry into endothelial cells and activates BK channels independently of G-protein coupled receptors","volume":"169","author":"Bondarenko","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0270","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00424-010-0898-x","article-title":"The GPR55 agonist lysophosphatidylinositol acts as an intracellular messenger and bidirectionally modulates Ca2+ -activated large-conductance K+ channels in endothelial cells","volume":"461","author":"Bondarenko","year":"2011","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.vph.2026.107671_bb0275","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1111\/bph.13889","article-title":"Big conductance calcium-activated potassium channel openers control spasticity without sedation","volume":"174","author":"Baker","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0280","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1080\/19336950.2021.1910461","article-title":"Potassium channels as molecular targets of endocannabinoids","volume":"15","author":"Lin","year":"2021","journal-title":"Channels"},{"key":"10.1016\/j.vph.2026.107671_bb0285","first-page":"C77","article-title":"Activation of large-conductance, Ca2+-activated K+ channels by cannabinoids","volume":"290","author":"Sade","year":"2006","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.vph.2026.107671_bb0290","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1469-7793.2001.t01-1-00641.x","article-title":"The mechanism of phenylephrine-mediated [Ca2+ ]i oscillations underlying tonic contraction in the rabbit inferior vena cava","volume":"534","author":"Lee","year":"2001","journal-title":"J. Physiol."},{"key":"10.1016\/j.vph.2026.107671_bb0295","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ceca.2013.12.005","article-title":"Effects of endogenous cannabinoid anandamide on excitation-contraction coupling in rat ventricular myocytes","volume":"55","author":"Al Kury","year":"2014","journal-title":"Cell Calcium"},{"key":"10.1016\/j.vph.2026.107671_bb0300","doi-asserted-by":"crossref","first-page":"13106","DOI":"10.1523\/JNEUROSCI.2919-09.2009","article-title":"T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids","volume":"29","author":"Barbara","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.vph.2026.107671_bb0305","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.1093\/emboj\/20.24.7033","article-title":"Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide","volume":"20","author":"Chemin","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.vph.2026.107671_bb0310","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-3-030-04278-3_3","article-title":"Regulation of BK channel activity by cholesterol and its derivatives","volume":"1115","author":"Bukiya","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.vph.2026.107671_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105508","article-title":"Understanding the complex pharmacology of cannabidiol: mounting evidence suggests a common binding site with cholesterol","volume":"166","author":"Martin","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.vph.2026.107671_bb0320","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2710.2011.01284.x","article-title":"CB1-independent mechanisms of \u03949-THCV, AM251 and SR141716 (rimonabant): CB1-independent mechanisms","volume":"37","author":"Raffa","year":"2012","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.vph.2026.107671_bb0325","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1007\/s00018-019-03433-6","article-title":"The cannabinoid ligands SR141716A and AM251 enhance human and mouse islet function via GPR55-independent signalling","volume":"77","author":"Ruz-Maldonado","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.vph.2026.107671_bb0330","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/hy0202.102702","article-title":"CB1 receptor antagonist SR141716A inhibits Ca2+-induced relaxation in CB1 receptor-deficient mice","volume":"39","author":"Bukoski","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2026.107671_bb0335","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/sj.bjp.0702127","article-title":"The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery","volume":"125","author":"White","year":"1998","journal-title":"Bt. J. Pharm."},{"key":"10.1016\/j.vph.2026.107671_bb0340","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.phrs.2016.08.028","article-title":"The endocannabinoid anandamide causes endothelium-dependent vasorelaxation in human mesenteric arteries","volume":"113","author":"Stanley","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.vph.2026.107671_bb0345","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/cvr\/cvv179","article-title":"Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation","volume":"107","author":"Stanley","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.vph.2026.107671_bb0350","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/sj.bjp.0703521","article-title":"Influence of cannabinoids on the delayed rectifier in freshly dissociated smooth muscle cells of the rat aorta","volume":"131","author":"Van den Bossche","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0355","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.107.125336","article-title":"The endogenous cannabinoid anandamide inhibits cromakalim-activated K+ currents in follicle-enclosed xenopus oocytes","volume":"323","author":"Oz","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.vph.2026.107671_bb0360","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1113\/jphysiol.1996.sp021288","article-title":"Calcium-activated potassium channels in the endothelium of intact rat aorta","volume":"492","author":"Marchenko","year":"1996","journal-title":"J. Physiol."},{"key":"10.1016\/j.vph.2026.107671_bb0365","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1476-5381.2009.00132.x","article-title":"Endothelial Ca2+ -activated K+ channels in normal and impaired EDHF\u2013dilator responses \u2013 relevance to cardiovascular pathologies and drug discovery","volume":"157","author":"Grgic","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0370","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1440-1681.2004.04053.x","article-title":"Endothelial potassium channels, endothelium-dependent hyperpolarization and the regulation of vascular tone in health and disease","volume":"31","author":"Coleman","year":"2004","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.vph.2026.107671_bb0375","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1006\/bbrc.1998.9877","article-title":"Role of heterocellular Gap junctional communication in endothelium-dependent smooth muscle hyperpolarization: inhibition by a connexin-mimetic peptide","volume":"254","author":"Dora","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.vph.2026.107671_bb0380","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/apha.12649","article-title":"EDH: endothelium-dependent hyperpolarization and microvascular signalling","volume":"219","author":"Garland","year":"2017","journal-title":"Acta Physiol."},{"key":"10.1016\/j.vph.2026.107671_bb0385","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1113\/jphysiol.2003.051896","article-title":"Small- and intermediate-conductance calcium-activated K+ channels provide different facets of endothelium-dependent hyperpolarization in rat mesenteric artery","volume":"553","author":"Crane","year":"2003","journal-title":"J. Physiol."},{"key":"10.1016\/j.vph.2026.107671_bb0390","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.bjp.0705866","article-title":"Sodium-calcium exchanger contributes to membrane hyperpolarization of intact endothelial cells from rat aorta during acetylcholine stimulation","volume":"143","author":"Bondarenko","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0395","first-page":"H804","article-title":"Smooth muscle cells affect endothelial membrane potential in rat aorta","volume":"267","author":"Marchenko","year":"1994","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.vph.2026.107671_bb0400","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1469-7793.2001.00181.x","article-title":"Intercellular electrical communication among smooth muscle and endothelial cells in guinea-pig mesenteric arterioles","volume":"535","author":"Yamamoto","year":"2001","journal-title":"J. Physiol."},{"key":"10.1016\/j.vph.2026.107671_bb0405","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1172\/JCI119677","article-title":"Production and physiological actions of anandamide in the vasculature of the rat kidney","volume":"100","author":"Deutsch","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vph.2026.107671_bb0410","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1006\/bbrc.1996.1766","article-title":"An endogenous cannabinoid as an endothelium-derived vasorelaxant","volume":"229","author":"Randall","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.vph.2026.107671_bb0415","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/sj.bjp.0701546","article-title":"A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery","volume":"122","author":"White","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0420","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/sj.bjp.0705160","article-title":"Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery","volume":"138","author":"Ho","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0425","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/sj.bjp.0706687","article-title":"Cannabinoid agonists induce relaxation in the bovine ophthalmic artery: evidences for CB1 receptors, nitric oxide and potassium channels","volume":"147","author":"Romano","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0430","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejphar.2014.03.055","article-title":"Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature","volume":"735C","author":"MacIntyre","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0435","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.yjmcc.2018.01.002","article-title":"Ca2+-dependent potassium channels and cannabinoid signaling in the endothelium of apolipoprotein E knockout mice before plaque formation","volume":"115","author":"Bondarenko","year":"2018","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.vph.2026.107671_bb0440","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/sj.bjp.0701690","article-title":"Cannabinoid CB1 receptor and endothelium-dependent hyperpolarization in guinea-pig carotid, rat mesenteric and porcine coronary arteries","volume":"123","author":"Chataigneau","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0445","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.vph.2017.01.002","article-title":"GPR55 agonist lysophosphatidylinositol and lysophosphatidylcholine inhibit endothelial cell hyperpolarization via GPR-independent suppression of Na+-Ca2+ exchanger and endoplasmic reticulum Ca2+ refilling","volume":"89","author":"Bondarenko","year":"2017","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0450","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/sj.bjp.0706913","article-title":"Na+ -K+ -ATPase is involved in the sustained ACh-induced hyperpolarization of endothelial cells from rat aorta","volume":"149","author":"Bondarenko","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0455","first-page":"3485","article-title":"Effects of endogenous cannabinoid anandamide on cardiac Na\/Ca exchanger","volume":"171","author":"Al Kury","year":"2014","journal-title":"Cell Calcium"},{"key":"10.1016\/j.vph.2026.107671_bb0460","article-title":"Anandamide reduces intracellular Ca2+ concentration through suppression of Na+\/Ca2+ exchanger current in rat cardiac myocytes","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vph.2026.107671_bb0465","doi-asserted-by":"crossref","first-page":"6749","DOI":"10.1167\/iovs.10-6826","article-title":"Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, induces dilation of isolated porcine retinal arterioles: role of nitric oxide and potassium channels","volume":"52","author":"Omae","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.vph.2026.107671_bb0470","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1172\/JCI118041","article-title":"Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect","volume":"96","author":"Buchanan","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vph.2026.107671_bb0475","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cardiores.2004.12.025","article-title":"Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats","volume":"66","author":"Majithiya","year":"2005","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.vph.2026.107671_bb0480","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1161\/01.HYP.0000116303.71408.c2","article-title":"PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice","volume":"43","author":"Ryan","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2026.107671_bb0485","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1161\/01.HYP.24.2.170","article-title":"Effects of pioglitazone on calcium channels in vascular smooth muscle","volume":"24","author":"Zhang","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2026.107671_bb0490","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/13880209.2016.1255648","article-title":"Rational screening of peroxisome proliferator-activated receptor-\u03b3 agonists from natural products: potential therapeutics for heart failure","volume":"55","author":"Chen","year":"2017","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.vph.2026.107671_bb0495","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3892\/ol.2022.13474","article-title":"CDDO, a PPAR-gamma ligand, inhibits TPA-induced cell migration and invasion through a PPAR-gamma-independent mechanism","volume":"24","author":"Jang","year":"2022","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.vph.2026.107671_bb0500","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.pharep.2015.08.001","article-title":"Pioglitazone, an anti-diabetic drug requires sustained MAPK activation for its anti-tumor activity in MCF7 breast cancer cells, independent of PPAR-gamma pathway","volume":"68","author":"Kole","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.vph.2026.107671_bb0505","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.4049\/jimmunol.177.8.5068","article-title":"The peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma-independent mechanisms","volume":"177","author":"Ray","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.vph.2026.107671_bb0510","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1161\/01.HYP.21.6.1020","article-title":"Effects of ciglitazone on blood pressure and intracellular calcium metabolism","volume":"21","author":"Pershadsingh","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2026.107671_bb0515","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1111\/bph.12734","article-title":"Effects of endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytes","volume":"171","author":"Al Kury","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0520","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1476-5381.2012.01934.x","article-title":"Rosiglitazone selectively inhibits KATPchannels by acting on the KIR6 subunit","volume":"167","author":"Yu","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0525","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/108155890004800407","article-title":"Regulation of Ca(2+)-activated K+ currents by ciglitazone in rat pituitary GH3 cells","volume":"48","author":"Wu","year":"2000","journal-title":"J. Investig. Med."},{"key":"10.1016\/j.vph.2026.107671_bb0530","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3389\/fphar.2018.00977","article-title":"Pioglitazone, a PPAR-gamma activator, stimulates BKCa but suppresses IK M in hippocampal neurons","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0535","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s12272-012-0917-x","article-title":"Blockade of human HERG K+ channels by rosiglitazone, an antidiabetic drug","volume":"35","author":"Lee","year":"2012","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.vph.2026.107671_bb0540","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00210-006-0118-6","article-title":"Open channel block of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target for rosiglitazone","volume":"374","author":"Ahn","year":"2007","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0545","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1476-5381.2011.01210.x","article-title":"Rosiglitazone inhibits Kv4.3 potassium channels by open-channel block and acceleration of closed-state inactivation","volume":"163","author":"Jeong","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0550","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4196\/kjpp.2022.26.2.135","article-title":"The antidiabetic drug rosiglitazone blocks Kv1.5 potassium channels in an open state","volume":"26","author":"Lee","year":"2022","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0555","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1124\/mol.110.069922","article-title":"Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channels","volume":"79","author":"Majeed","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.178343","article-title":"PPAR\u03b3 ligands activate the ion channel TRPA1","volume":"1008","author":"Guenther","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0565","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/CAD.0b013e3280200414","article-title":"Peroxisome proliferator-activated receptor-\u03b3 antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines","volume":"18","author":"Burton","year":"2007","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.vph.2026.107671_bb0570","article-title":"Limited applicability of GW9662 to elucidate PPARgamma-mediated fatty acid effects in primary human T-helper cells","volume":"2014","author":"Jaudszus","year":"2014","journal-title":"Int. J. Inf. Secur."},{"key":"10.1016\/j.vph.2026.107671_bb0575","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/sj.bjp.0705973","article-title":"GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation","volume":"143","author":"Seargent","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0580","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1124\/mol.119.117887","article-title":"The peroxisome proliferator-activated receptor (PPAR)-gamma antagonist 2-Chloro-5-Nitro-N-Phenylbenzamide (GW9662) triggers perilipin 2 expression via PPAR delta and induces lipogenesis and triglyceride accumulation in human THP-1 macrophages","volume":"97","author":"Schubert","year":"2020","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0585","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.1021\/bi0159581","article-title":"Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662","volume":"41","author":"Leesnitzer","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.vph.2026.107671_bb0590","series-title":"Shifting the PPAR\u03b3 Conformational Ensemble Towards a Transcriptionally Repressive State Improves Covalent Inhibitor Efficacy","author":"Arifova","year":"2025"},{"key":"10.1016\/j.vph.2026.107671_bb0595","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/sj.bjp.0707352","article-title":"Interaction of ligands for the peroxisome proliferator-activated receptor \u03b3 with the endocannabinoid system","volume":"151","author":"Lenman","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0600","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1124\/mol.109.056911","article-title":"Peroxisome proliferator-activated receptor \u03b3 antagonists decrease Na+ transport via the epithelial Na+ channel","volume":"76","author":"Pavlov","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0605","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93760","article-title":"A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study","volume":"2","author":"Jadoon","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.vph.2026.107671_bb0610","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0014-2999(01)01112-8","article-title":"Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors","volume":"423","author":"Wagner","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.vph.2026.107671_bb0615","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123602","article-title":"Palmitoylethanolamide treatment reduces blood pressure in spontaneously hypertensive rats: involvement of cytochrome P450-derived eicosanoids and renin angiotensin system","volume":"10","author":"Mattace Raso","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vph.2026.107671_bb0620","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1161\/HYPERTENSIONAHA.111.01076","article-title":"Human \u03b2-defensin 2 is a novel opener of Ca2+ -activated potassium channels and induces vasodilation and hypotension in monkeys","volume":"62","author":"Liu","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2026.107671_bb0625","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2026.107671_bb0630","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/1074248411425490","article-title":"Rosiglitazone causes endothelial dysfunction in humans","volume":"17","author":"Perampaladas","year":"2012","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.vph.2026.107671_bb0635","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/dom.14687","article-title":"Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance","volume":"24","author":"Spence","year":"2022","journal-title":"Diabetes Obes. Metab."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189126000911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189126000911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:33:14Z","timestamp":1788579194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189126000911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":127,"alternative-id":["S1537189126000911"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2026.107671","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reassessing the role of PPARgamma in vascular effects of cannabinoids: A critical appraisal","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2026.107671","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107671"}}